Regulation of natural killer cell function by STAT3

Frontiers in Immunology

Volumn 7, Issue APR, 2016, Pages

  Cacalano, Nicholas A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer immunology; Chemokines; Cytokines; Natural killer cells; Signal transducer and activator of transcription; STAT3 transcription factor

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; CHEMOKINE; CILIARY NEUROTROPHIC FACTOR; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; INDOLEAMINE 2,3 DIOXYGENASE; INTRINSIC FACTOR; JANUS KINASE; LEUKEMIA INHIBITORY FACTOR; ONCOSTATIN M; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN RECEPTOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; APOPTOSIS; CARCINOGENESIS; CELL COMMUNICATION; CELL CYCLE CHECKPOINT; CELL DIFFERENTIATION; CELL FUNCTION; CELL INFILTRATION; CELL INTERACTION; CELL KILLING; CELL MIGRATION; CELL PROLIFERATION; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; ONCOGENE SRC; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECOGNITION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSPLANTATION; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84966783578     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00128     Document Type: Review

References (217)

1. Cella M, Miller H, Song C. Beyond NK cells: the expanding universe of innate lymphoid cells. Front Immunol (2014) 5:1-11. doi:10.3389/fimmu.2014.00282
2. Artis D, Spits H. The biology of innate lymphoid cells. Nature (2015) 517:293-301. doi:10.1038/nature14189
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013
4. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 21:309-22. doi:10.1016/j.ccr.2012.02.022
5. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol (2008) 9:503-10. doi:10.1038/ni1582
6. Montaldo E, Vacca P, Moretta L, Mingari MC. Development of human natural killer cells and other innate lymphoid cells. Semin Immunol (2014) 26:107-13. doi:10.1016/j.smim.2014.01.006
7. Moretta L, Montaldo E, Vacca P, Del Zotto G, Moretta F, Merli P, et al. Human natural killer cells: origin, receptors, function, and clinical applications. Int Arch Allergy Immunol (2014) 164:253-64. doi:10.1159/000365632
8. Shifrin N, Raulet DH, Ardolino M. NK cell self tolerance, responsiveness and missing self recognition. Semin Immunol (2014) 26:138-44. doi:10.1016/j.smim.2014.02.007
9. Keating SE, Ní Chorcora C, Dring MM, Stallings RL, O'Meara A, Gardiner CM. Increased frequencies of the killer immunoglobulin-like receptor genes KIR2DL2 and KIR2DS2 are associated with neuroblastoma. Tissue Antigens (2015) 86:172-7. doi:10.1111/tan.12608
10. Rocca YS, Roberti MP, Arriaga JM, Amat M, Bruno L, Pampena MB, et al. Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients. Innate Immun (2013) 19:76-85. doi:10.1177/1753425912453187
11. Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer (2008) 112:863-75. doi:10.1002/cncr.23239
12. Schleypen JS, Baur N, Kammerer R, Nelson PJ, Rohrmann K, Gröne EF, et al. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res (2006) 12:718-25. doi:10.1158/1078-0432.CCR-05-0857
13. Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P, et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res (2011) 71:5412-22. doi:10.1158/0008-5472.CAN-10-4179
14. Koo KC, Shim DH, Yang CM, Lee SB, Kim SM, Shin TY, et al. Reduction of the CD16(-)CD56bright NK cell subset precedes NK cell dysfunction in prostate cancer. PLoS One (2013) 8:e78049. doi:10.1371/journal.pone.0078049
15. Nishimura Y, Kumagai-Takei N, Matsuzaki H, Lee S, Maeda M, Kishimoto T, et al. Functional alteration of natural killer cells and cytotoxic T lymphocytes upon asbestos exposure and in malignant mesothelioma patients. Biomed Res Int (2015) 2015:238431. doi:10.1155/2015/238431
16. Messaoudene M, Périer A, Fregni G, Neves E, Zitvogel L, Cremer I, et al. Characterization of the microenvironment in positive and negative sentinel lymph nodes from melanoma patients. PLoS One (2015) 10:e0133363. doi:10.1371/journal.pone.0133363
17. Bottino C, Dondero A, Bellora F, Moretta L, Locatelli F, Pistoia V, et al. Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches. Front Immunol (2014) 5:56. doi:10.3389/fimmu.2014.00056
18. Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol (2008) 2008(129):428-37. doi:10.1016/j.clim.2008.08.012
19. Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A, et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res (2012) 72:1407-15. doi:10.1158/0008-5472.CAN-11-2544
20. Wölfle SJ, Strebovsky J, Bartz H, Sähr A, Arnold C, Kaiser C, et al. PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol (2011) 41:413-24. doi:10.1002/eji.201040979
21. Sumpter TL, Thomson AW. The STATus of PD-L1 (B7-H1) on tolerogenic APCs. Eur J Immunol (2011) 41:286-90. doi:10.1002/eji.201041353
22. Azoulay-Alfaguter I, Strazza M, Pedoeem A, Mor A. The coreceptor programmed death 1 inhibits T-cell adhesion by regulating Rap1. J Allergy Clin Immunol (2015) 135:564-7. doi:10.1016/j.jaci.2014.07.055
23. Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ, Mor A. Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol (2014) 153:145-52. doi:10.1016/j.clim.2014.04.010
24. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 27:450-61. doi:10.1016/j.ccell.2015.03.001
25. Brahmer JR, Pardoll DM. Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res (2013) 1:85-91. doi:10.1158/2326-6066.CIR-13-0078
26. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 24:207-12. doi:10.1016/j.coi.2011.12.009
27. Cantoni C, Grauwet K, Pietra G, Parodi M, Mingari MC, Maria A, et al. Role of NK cells in immunotherapy and virotherapy of solid tumors. Immunotherapy (2015) 7(8):861-82. doi:10.2217/imt.15.53
28. Gras Navarro A, Björklund AT, Chekenya M. Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol (2015) 6:202. doi:10.3389/fimmu.2015.00202
29. Mahmood S, Upreti D, Sow I, Amari A, Nandagopal S, Kung SK. Bidirectional interactions of NK cells and dendritic cells in immunotherapy: current and future perspective. Immunotherapy (2015) 7:301-8
30. Zheng Y, Dou Y, Duan L, Cong C, Gao A, Lai Q, et al. Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer. Cell Immunol (2015) 294:54-9. doi:10.1016/j.cellimm.2015.02.003
31. Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology (2009) 126:458-65. doi:10.1111/j.1365-2567.2008.03027.x
32. Jewett A, Man YG, Tseng HC. Dual functions of natural killer cells in selection and differentiation of stem cells; role in regulation of inflammation and regeneration of tissues. J Cancer (2013) 4:12-24. doi:10.7150/jca.5519
33. Jewett A, Tseng H-C. Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells. J Cancer (2011) 2:443-57. doi:10.7150/jca.2.443
34. Jewett A, Head C, Cacalano NA. Emerging mechanisms of immunosuppression in oral cancers. J Dent Res (2006) 85:1061-73. doi:10.1177/154405910608501201
35. Jewett A, Bonavida B. Target-induced inactivation and cell death by apoptosis in a subset of human NK cells. Immunol J (1996) 156:907-15
36. Jewett A, Bonavida B. Target-induced anergy of natural killer cytotoxic function is restricted to the NK-target conjugate subset. Cell Immunol (1995) 160:91-7. doi:10.1016/0008-8749(95)80013-9
37. Tseng HC, Arasteh A, Paranjpe A, Teruel A, Yang W, Behel A, et al. Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or re-programming activates NK cells. PLoS One (2010) 5:e11590. doi:10.1371/journal.pone.0011590
38. Magister Š, Tseng HC, Bui VT, Kos J, Jewett A. Regulation of split anergy in natural killer cells by inhibition of cathepsins C and H and cystatin F. Oncotarget (2015) 6(26):22310-27. doi:10.18632/oncotarget.4208
39. Cacalano NA, Johnston JA. Interleukin-2 signaling and inherited immunodeficiency. Am J Hum Genet (1999) 65:287-93. doi:10.1086/302518
40. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity (2012) 36(4):503-14. doi:10.1016/j.immuni.2012.03.013
41. Schindler C, Plumlee C. Inteferons pen the JAK-STAT pathway. Semin Cell Dev Biol (2008) 19:311-8. doi:10.1016/j.semcdb.2008.08.010
42. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem (2007) 282:20059-63. doi:10.1074/jbc.R700016200
43. Villarino AV, Kanno Y, Ferdinand JR, O'Shea JJ. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol (2015) 194:21-7. doi:10.4049/jimmunol.1401867
44. Cao Q, Li YY, He WF, Zhang ZZ, Zhou Q, Liu X, et al. Interplay between microRNAs and the STAT3 signaling pathway in human cancers. Physiol Genomics (2013) 45:1206-14. doi:10.1152/physiolgenomics.00122.2013
45. Vogel TP, Milner JD, Cooper MA. The Ying and Yang of STAT3 in human disease. J Clin Immunol (2015) 35(7):615-23. doi:10.1007/s10875-015-0187-8
46. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer (2014) 14:736-46. doi:10.1038/nrc3818
47. Li N, Grivennikov SI, Karin M. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell (2011) 19:429-31. doi:10.1016/j.ccr.2011.03.018
48. Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol (2014) 26:54-74. doi:10.1016/j.smim.2014.01.001
49. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci (2009) 1171:59-76. doi:10.1111/j.1749-6632.2009.04911.x
50. Wendt MK, Balanis N, Carlin CR, Schiemann WP. STAT3 and epithelial-mesenchymal transitions in carcinomas. JAKSTAT (2014) 3:e28975. doi:10.4161/jkst.28975
51. Zhu QC, Gao RY, Wu W, Qin HL. Epithelial-mesenchymal transition and its role in the pathogenesis of colorectal cancer. Asian Pac J Cancer Prev (2013) 14:2689-98. doi:10.7314/APJCP.2013.14.5.2689
52. Duan S, Tsai Y, Keng P, Chen Y, Lee SO, Chen Y. IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules. Oncotarget (2015) 6:27651-60. doi:10.18632/oncotarget.4753
53. Lau J, Ilkhanizadeh S, Wang S, Miroshnikova YA, Salvatierra NA, Wong RA, et al. STAT3 blockade inhibits radiation-induced malignant progression in glioma. Cancer Res (2015) 75(20):4302-11. doi:10.1158/0008-5472.CAN-14-3331
54. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 9:798-809. doi:10.1038/nrc2734
55. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med (2005) 11:1314-21. doi:10.1038/nm1325
56. Kortylewski M, Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol (2008) 20:228-33. doi:10.1016/j.coi.2008.03.010
57. Kortylewski M, Yu H. Stat3 as a potential target for cancer immunotherapy. J Immunother (2007) 30:131-9. doi:10.1097/01.cji.0000211327.76266.65
58. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol (2007) 7:41-51. doi:10.1038/nri1995
59. Gotthardt D, Putz EM, Straka E, Kudweis P, Biaggio M, Poli V, et al. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood (2014) 124:2370-9. doi:10.1182/blood-2014-03-564450
60. Vacca P, Cantoni C, Prato C, Fulcheri E, Moretta A, Moretta L, et al. Regulatory role of NKp44, NKp46, DNAM-1 and NKG2D receptors in the interaction between NK cells and trophoblast cells. Evidence for divergent functional profiles of decidual versus peripheral NK cells. Int Immunol (2008) 20:1395-405. doi:10.1093/intimm/dxn105
61. Cerboni C, Fionda C, Soriani A, Zingoni A, Doria M, Cippitelli M, et al. The DNA damage response: a common pathway in the regulation of NKG2D and DNAM-1 ligand expression in normal, infected, and cancer cells. Front Immunol (2014) 4:508. doi:10.3389/fimmu.2013.00508
62. de Andrade LF, Smyth MJ, Martinet L. DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins. Immunol Cell Biol (2014) 92:237-44. doi:10.1038/icb.2013.95
63. Fionda C, Soriani A, Zingoni A, Santoni A, Cippitelli M. NKG2D and DNAM-1 ligands: molecular targets for NK cell-mediated immunotherapeutic intervention in multiple myeloma. Biomed Res Int (2015) 2015:178698. doi:10.1155/2015/178698
64. Morisaki T, Onishi H, Katano M. Cancer immunotherapy using NKG2D and DNAM-1 systems. Anticancer Res (2012) 32:2241-7
65. Elishmereni M, Bachelet I, Levi-Schaffer F. DNAM-1: an amplifier of immune responses as a therapeutic target in various disorders. Curr Opin Investig Drugs (2008) 9:491-6
66. Kida H, Ihara S, Kumanogoh A. Involvement of STAT3 in immune evasion during lung tumorigenesis. Oncoimmunology (2013) 2(1):e22653. doi:10.4161/onci.22653
67. Gismondi A, Santoni A. Migration of NK cells. In: Badolato R, Sozzani S, editors. Lymphocyte Trafficking in Health and Disease. Basel: Birkhauser Verlag (2006). 95 p
68. Allavena P, Bianchi G, Zhou D, van Damme J, Jilek P, Sozzani S, et al. Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol (1994) 24:3233-6. doi:10.1002/eji.1830241249
69. Gregiore C, Chasson L, Luci C, Tomasello E, Geissmann F, Vivier E, et al. The trafficking of natural killer cells. Immunol Rev (2007) 220:169-82. doi:10.1111/j.1600-065X.2007.00563.x
70. Nokihara H, Yanagawa H, Nishioka Y, Yano S, Mukaida N, Matsushima K, et al. Natural killer cell-dependent suppression of systemic spread of human lung adenocarcinoma cells by monocyte chemoattractant protein-1 gene transfection in severe combined immunodeficient mice. Cancer Res (2000) 60:7002-7
71. Mukaida N, Sasaki S, Baba T. Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment. Mediators Inflamm (2014) 2014:170381. doi:10.1155/2014/170381
72. Halama N, Braun M, Kahlert C, Spille A, Quack C, Rahbari N, et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Can Res (2011) 17:678-89. doi:10.1158/1078-0432.CCR-10-2173
73. Tsuchiyama T, Nakamoto Y, Sakai Y, Marukawa Y, Kitahara M, Mukaida N, et al. Prolonged, NK cell-mediated antitumor effects of suicide gene therapy combined with monocyte chemoattractant protein-1 against hepatocellular carcinoma. J Immunol (2007) 178:574-83. doi:10.4049/jimmunol.178.1.574
74. Lavergne E, Combadière B, Bonduelle O, Iga M, Gao JL, Maho M, et al. Fractalkine mediates natural killer-dependent antitumor responses in vivo. Cancer Res (2003) 63:7468-74
75. Tang L, Hu HD, Hu P, Lan YH, Peng ML, Chen M, et al. Gene therapy with CX3CL1/fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma. Gene Ther (2007) 14:1226-34. doi:10.1038/sj.gt.3302959
76. Zeng Y, Huebener N, Fest S, Weixler S, Schroeder U, Gaedicke G, et al. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Cancer Res (2007) 67:2331-8. doi:10.1158/0008-5472.CAN-06-3041
77. Burdelya L, Kujawski M, Niu G, Zhong B, Wang T, Zhang S, et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol (2005) 174:3925-31. doi:10.4049/jimmunol.174.7.3925
78. Ihara S, Kida H, Arase H, Tripathi LP, Chen Y-A, Kimura T, et al. Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis. Cancer Res (2012) 72:2990-9. doi:10.1158/0008-5472.CAN-11-4062
79. Putz EM, Hoelzl MA, Baeck J, Bago-Horvath Z, Schuster C, Reichholf B, et al. Loss of STAT3 in lymphoma relaxes NK cell-mediated tumor surveillance. Cancers (Basel) (2014) 6:193-210. doi:10.3390/cancers6010193
80. Chretien AS, Le Roy A, Vey N, Prebet T, Blaise D, Fauriat C, et al. Cancer-induced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity. Front Immunol (2014) 5:122. doi:10.3389/fimmu.2014.00122
81. Marcus A, Gowen BG, Thompson TW, Iannello A, Ardolino M, Deng W, et al. Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol (2014) 122:91-128. doi:10.1016/B978-0-12-800267-4.00003-1
82. Baychelier F, Vieillard V. The modulation of the cell-cycle: a sentinel to alert the NK cells of dangers. Front Immunol (2013) 4:325. doi:10.3389/fimmu.2013.00325
83. Lam RA, Chwee JY, Le Bert N, Sauer M, Pogge von Strandmann E, Gasser S. Regulation of self-ligands for activating natural killer cell receptors. Ann Med (2013) 45:384-94. doi:10.3109/07853890.2013.792495
84. Gasser S, Raulet DH. The DNA damage response arouses the immune system. Cancer Res (2006) 66:3959-62. doi:10.1158/0008-5472.CAN-05-4603
85. Lanier LL. NKG2D receptor and its ligands in host defense. Cancer Immunol Res (2015) 3:575-82. doi:10.1158/2326-6066.CIR-15-0098
86. Chen D, Gyllensten U. MICA polymorphism: biology and importance in cancer. Carcinogenesis (2014) 35(12):2633-42. doi:10.1093/carcin/bgu215
87. Goto K, Kato N. MICA SNPs and the NKG2D system in virus-induced HCC. J Gastroenterol (2015) 50:261-72. doi:10.1007/s00535-014-1000-9
88. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev (2010) 235:267-85. doi:10.1111/j.0105-2896.2010.00893.x
89. Huergo-Zapico L, Acebes-Huerta A, López-Soto A, Villa-álvarez M, Gonzalez-Rodriguez AP, Gonzalez S. Molecular bases for the regulation of NKG2D ligands in cancer. Front Immunol (2014) 5:106. doi:10.3389/fimmu.2014.00106
90. Spear P, Wu MR, Sentman ML, Sentman CL. NKG2D ligands as therapeutic targets. Cancer Immun (2013) 13:8
91. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity (2008) 28:571-80. doi:10.1016/j.immuni.2008.02.016
92. Arreygue-Garcia NA, Daneri-Navarro A, del Toro-Arreola A, Cid-Arregui A, Gonzalez-Ramella O, Jave-Suarez LF, et al. Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer (2008) 8:16. doi:10.1186/1471-2407-8-16
93. Bedel R, Thiery-Vuillemin A, Grandclement C, Balland J, Remy-Martin JP, Kantelip B, et al. Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells. Cancer Res (2011) 71:1615-26. doi:10.1158/0008-5472.CAN-09-4540
94. Fionda C, Malgarini G, Soriani A, Zingoni A, Cecere F, Iannitto ML, et al. Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3. J Immunol (2013) 190:6662-72. doi:10.4049/jimmunol.1201426
95. Zhu S, Phatarpekar PV, Denman CJ, Senyukov VV, Somanchi SS, Nguyen-Jackson HT, et al. Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation. Blood (2014) 124:403-11. doi:10.1182/blood-2013-05-499707
96. Takaki R, Hayakawa Y, Nelson A, Sivakumar PV, Hughes S, Smyth MJ, et al. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J Immunol (2005) 175(4):2167-73
97. Burgess SJ, Marusina AI, Pathmanathan I, Borrego F, Coligan JE. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD81 T cells. J Immunol (2006) 176:1490-7. doi:10.4049/jimmunol.176.3.1490
98. Wan CK, Andraski AB, Spolski R, Li P, Kazemian M, Oh J, et al. Opposing roles of STAT1 and STAT3 in IL-21 function in CD4+ T cells. Proc Natl Acad Sci U S A (2015) 112:9394-9. doi:10.1073/pnas.1511711112
99. Ramsay AG. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. Br J Haematol (2013) 162:313-25. doi:10.1111/bjh.12380
100. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell (2015) 161:205-14. doi:10.1016/j.cell.2015.03.030
101. Sharma P, Allison JP. The future of immune checkpoint therapy. Science (2015) 348:56-61. doi:10.1126/science.aaa8172
102. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med (2014) 65:185-202. doi:10.1146/annurev-med-092012-112807
103. Monteiro J. Timeline: checkpoint blockade. Cell (2015) 162:1434. doi:10.1016/j.cell.2015.08.019
104. Littman DR. Releasing the brakes on cancer immunotherapy. Cell (2015) 162:1186-90. doi:10.1016/j.cell.2015.08.038
105. Kyi C, Postow MA. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett (2014) 588:368-76. doi:10.1016/j.febslet.2013.10.015
106. Ito A, Kondo S, Tada K, Kitano S. Clinical development of immune checkpoint inhibitors. Biomed Res Int (2015) 2015:605478. doi:10.1155/2015/605478
107. Anagnostou VK, Brahmer JR. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res (2015) 21:976-84. doi:10.1158/1078-0432.CCR-14-1187
108. Parmiani G, Maccalli C, Maio M. Integrating immune checkpoint blockade with anti-neo/mutated antigens reactivity to increase the clinical outcome of immunotherapy. Vaccines (Basel) (2015) 3:420-8. doi:10.3390/vaccines3020420
109. Kreamer KM. Immune checkpoint blockade: a new paradigm in treating advanced cancer. J Adv Pract Oncol (2014) 5:418-31
110. Callahan MK, Wolchok JD. Clinical activity, toxicity, biomarkers, and future development of CTLA-4 checkpoint antagonists. Semin Oncol (2015) 42:573-86. doi:10.1053/j.seminoncol.2015.05.008
111. Mashima E, Inoue A, Sakuragi Y, Yamaguchi T, Sasaki N, Hara Y, et al. Nivolumab in the treatment of malignant melanoma: review of the literature. Onco Targets Ther (2015) 8:2045-51. doi:10.2147/OTT.S62102
112. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 369:134-44. doi:10.1056/NEJMoa1305133
113. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med (2015) 372:2521-32. doi:10.1056/NEJMoa1503093
114. Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer (2015) 112:1421-7. doi:10.1038/bjc.2015.124
115. Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol (2015) 33:23-35. doi:10.1016/j.coi.2015.01.006
116. Knaus HA, Kanakry CG, Luznik L, Gojo I. Immunomodulatory drugs II: immune checkpoint agents in acute leukemia. Curr Drug Targets (2015)
117. Cohen J, Sznol M. Therapeutic combinations of immune-modulating antibodies in melanoma and beyond. Semin Oncol (2015) 42:488-94. doi:10.1053/j.seminoncol.2015.02.014
118. Harvey RD. Immunologic and clinical effects of targeting PD-1 in lung cancer. Clin Pharmacol Ther (2014) 96:214-23. doi:10.1038/clpt.2014.74
119. Covre A, Coral S, Di Giacomo AM, Taverna P, Azab M, Maio M. Epigenetics meets immune checkpoints. Semin Oncol (2015) 42:506-13. doi:10.1053/j.seminoncol.2015.02.003
120. Jang JH, Huang Y, Zheng P, Jo MC, Bertolet G, Zhu MX, et al. Imaging of cell-cell communication in a vertical orientation reveals high-resolution structure of immunological synapse and novel PD-1 dynamics. J Immunol (2015) 195:1320-30. doi:10.4049/jimmunol.1403143
121. Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A (2008) 105:20852-7. doi:10.1073/pnas.0810958105
122. Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood (2010) 116:2286-94. doi:10.1182/blood-2010-02-271874
123. Ferlazzo G, Morandi B. Cross-talks between natural killer cells and distinct subsets of dendritic cells. Front Immunol (2014) 5:159. doi:10.3389/fimmu.2014.00159
124. Wong JL, Mailliard RB, Moschos SJ, Edington H, Lotze MT, Kirkwood JM, et al. Helper activity of NK cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J Immunother (2011) 34:270-8. doi:10.1097/CJI.0b013e31820b370b
125. Ferlazzo G, Moretta L. Dendritic cell editing by natural killer cells. Crit Rev Oncog (2014) 19:67-75. doi:10.1615/CritRevOncog.2014010827
126. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor micro-environment: expect the unexpected. J Clin Invest (2015) 125:3356-64. doi:10.1172/JCI80005
127. Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Adv Cancer Res (2015) 128:95-139. doi:10.1016/bs.acr.2015.04.002
128. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer (2013) 13:739-52. doi:10.1038/nrc3581
129. Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death Differ (2008) 15:226-33. doi:10.1038/sj.cdd.4402170
130. Castriconi R, Della Chiesa M, Moretta A. Shaping of adaptive immunity by innate interactions. C R Biol (2004) 327:533-7. doi:10.1016/j.crvi.2003.12.001
131. Pampena MB, Levy EM. Natural killer cells as helper cells in dendritic cell cancer vaccines. Front Immunol (2015) 6:13. doi:10.3389/fimmu.2015.00013
132. Sconocchia G, Eppenberger S, Spagnoli GC, Tornillo L, Droeser R, Caratelli S, et al. NK cells and T cells cooperate during the clinical course of colorectal cancer. Oncoimmunology (2014) 3:e952197. doi:10.4161/21624011.2014.952197
133. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science (2011) 331:44-9. doi:10.1126/science.1198687
134. Chaix J, Tessmer MS, Hoebe K, Fuséri N, Ryffel B, Dalod M, et al. Cutting edge: priming of NK cells by IL-18. J Immunol (2008) 181:1627-31. doi:10.4049/jimmunol.181.3.1627
135. Gabrilovich DI, Ciernik IF, Carbone DP. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol (1996) 170:101-10. doi:10.1006/cimm.1996.0139
136. Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP. Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cell Immunol (1996) 170:111. doi:10.1006/cimm.1996.0140
137. Gabrilovich DI, Corak J I, Ciernik F, Kavanaugh D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res (1997) 3:483
138. Almand B, Clark JI, Nikitina E, English NR, Knight SC, Carbone DP, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol (2001) 166:678. doi:10.4049/jimmunol.166.1.678
139. Almand B, Resser J, Lindman B, Nadaf S, Clark J, Kwon E, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res (2000) 6:1755
140. Thurnher M, Radmayar C, Ramoner R, Ebner S, Bock G, Klocker H, et al. Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer (1996) 67:1. doi:10.1002/(SICI)1097-0215(19960927)68:1<1::AID-IJC1>3.0.CO;2-V
141. Nestle FO, Burg G, Fah J, Wrone-Smith T, Nickoloff BJ. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol (1997) 150:641
142. Chaux P, Moutet M, Faivre J, Martin F, Martin M. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab Invest (1996) 74:975
143. Chaux P, Favre N, Martin M, Martin F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int J Cancer (1997) 72:619. doi:10.1002/(SICI)1097-0215(19970807)72:4<619::AID-IJC12>3.0.CO;2-6
144. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med (1996) 2:1096-103. doi:10.1038/nm1096-1096
145. Gabrilovich DI, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood (1998) 92:4150
146. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol (2001) 166:5398-406. doi:10.4049/jimmunol.166.9.5398
147. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol (2004) 4(12):941-52. doi:10.1038/nri1498
148. Nefedova Y, Cheng P, Gilkes D, Blaskovich M, Beg AA, Sebti SM, et al. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol (2005) 175:4338-46. doi:10.4049/jimmunol.175.7.4338
149. Nefedova Y, Huang M, Kusmartsev S, Bhattacharya R, Cheng P, Salup R, et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol (2004) 172:464-74. doi:10.4049/jimmunol.172.1.464
150. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2004) 10:48-54. doi:10.1038/nm976
151. Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell (2009) 15:114-23. doi:10.1016/j.ccr.2008.12.018
152. Sieve AN, Meeks KD, Lee S, Berg RE. A novel immunoregulatory function for IL-23: inhibition of IL-12 dependent IFN-γ production. Eur J Immunol (2010) 40:2236-47. doi:10.1002/eji.200939759
153. Floss DM, Schröder J, Franke M, Scheller J. Insights into IL-23 biology: from structure to function. Cytokine Growth Factor Rev (2015) 26(5):569-78. doi:10.1016/j.cytogfr.2015.07.005
154. Magram J, Connaughton SE, Warrier RR, Carvajal DM, Wu CY, Ferrante J, et al. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity (1996) 4:471-81. doi:10.1016/S1074-7613(00)80413-6
155. Sanal O, Turkkani G, Gumruk F, Yel L, Secmeer G, Tezcan I, et al. A case of interleukin-12 receptor beta-1 deficiency with recurrent leishmaniasis. Pediatr Infect Dis J (2007) 26:366-8. doi:10.1097/01.inf.0000258696.64507.0f
156. Gazzinelli RT, Hieny S, Wynn TA, Wolf S, Sher A. Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci U S A (1993) 90:6115-9. doi:10.1073/pnas.90.13.6115
157. Haraguchi S, Day NK, Nelson RP Jr, Emmanuel P, Duplantier JE, Christodoulou CS, et al. Interleukin 12 deficiency associated with recurrent infections. Proc Natl Acad Sci U S A (1998) 95:13125-9. doi:10.1073/pnas.95.22.13125
158. Palamaro L, Giardino G, Santamaria F, Romano R, Fusco A, Montella S, et al. Interleukin 12 receptor deficiency in a child with recurrent bronchopneumonia and very high IgE levels. Ital J Pediatr (2012) 2012(38):46
159. Meeran SM, Mantena SK, Meleth S, Elmets CA, Katiyar SK. Interleukin-12-deficient mice are at greater risk of UV radiation-induced skin tumors and malignant transformation of papillomas to carcinomas. Mol Cancer Ther (2006) 5:825-32. doi:10.1158/1535-7163.MCT-06-0003
160. Langowski JL, Kastelein RA, Oft M. Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol (2007) 28:207-12. doi:10.1016/j.it.2007.03.006
161. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, et al. IL-23 promotes tumour incidence and growth. Nature (2006) 442:461-5
162. Sucher R, Kurz K, Weiss G, Margreiter R, Fuchs D, Brandacher G. IDO-mediated tryptophan degradation in the pathogenesis of malignant tumor disease. Int J Tryptophan Res (2010) 3:113-20
163. Wobser M, Voigt H, Houben R, Eggert AO, Freiwald M, Kaemmerer U, et al. Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression. Cancer Immunol Immunother (2007) 56:1017-24. doi:10.1007/s00262-006-0256-1
164. Gostner JM, Becker K, Überall F, Fuchs D. The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment. Expert Opin Ther Targets (2015) 19:605-15. doi:10.1517/14728222.2014.995092
165. Pallotta MT, Fallarino F, Matino D, Macchiarulo A, Orabona C. AhR-mediated, non-genomic modulation of IDO1 function. Front Immunol (2014) 5:497. doi:10.3389/fimmu.2014.00497
166. Ball HJ, Jusof FF, Bakmiwewa SM, Hunt NH, Yuasa HJ. Tryptophan-catabolizing enzymes-party of three. Front Immunol (2014) 5:485. doi:10.3389/fimmu.2014.00485
167. Mándi Y, Vécsei L. The kynurenine system and immunoregulation. J Neural Transm (2012) 119:197-209. doi:10.1007/s00702-011-0681-y
168. Ling W, Zhang J, Yuan Z, Ren G, Zhang L, Chen X, et al. Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment. Cancer Res (2014) 74:1576-87. doi:10.1158/0008-5472.CAN-13-1656
169. Pfeifer S, Schreder M, Bolomsky A, Graffi S, Fuchs D, Sahota SS, et al. Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth. J Cancer Res Clin Oncol (2012) 138:1821-30. doi:10.1007/s00432-012-1259-2
170. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood (2008) 111:1327-33. doi:10.1182/blood-2007-02-074997
171. Peng YP, Zhang JJ, Liang WB, Tu M, Lu ZP, Wei JS, et al. Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction. BMC Cancer (2014) 14:738. doi:10.1186/1471-2407-14-738
172. Yu J, Wang Y, Yan F, Zhang P, Li H, Zhao H, et al. Noncanonical NF-κB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer. J Immunol (2014) 193:2574-86. doi:10.4049/jimmunol.1400833
173. Yu J, Du W, Yan F, Wang Y, Li H, Cao S, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol (2013) 190:3783-97. doi:10.4049/jimmunol.1201449
174. Campia I, Buondonno I, Castella B, Rolando B, Kopecka J, Gazzano E, et al. An autocrine cytokine/JAK/STAT-signaling induces kynurenine synthesis in multidrug resistant human cancer cells. PLoS One (2015) 10:e0126159. doi:10.1371/journal.pone.0126159
175. Litzenburger UM, Opitz CA, Sahm F, Rauschenbach KJ, Trump S, Winter M, et al. Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget (2014) 5:1038-51. doi:10.18632/oncotarget.1637
176. Chen JY, Li CF, Kuo CC, Tsai KK, Hou MF, Hung WC. Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression. Breast Cancer Res (2014) 16:410. doi:10.1186/s13058-014-0410-1
177. Yu Y, Xiao CH, Tan LD, Wang QS, Li XQ, Feng YM. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-β signalling. Br J Cancer (2014) 110:724-32. doi:10.1038/bjc.2013.768
178. Pardali K, Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta (2007) 1775:21-62
179. Chaudhury A, Howe PH. The tale of transforming growth factor-beta (TGFbeta) signaling: a soigné enigma. IUBMB Life (2009) 61:929-39. doi:10.1002/iub.239
180. Brunen D, Willems SM, Kellner U, Midgley R, Simon I, Bernards R. TGF β: an emerging player in drug resistance. Cell Cycle (2013) 12:2960-8. doi:10.4161/cc.26034
181. Padua D, Massagué J. Roles of TGFbeta in metastasis. Cell Res (2009) 19:89-102. doi:10.1038/cr.2008.316
182. Massagué J. TGFβ signalling in context. Nat Rev Mol Cell Biol (2012) 13:616-30. doi:10.1038/nrm3434
183. Castriconi R, Dondero A, Bellora F, Moretta L, Castellano A, Locatelli F, et al. Neuroblastoma-derived TGF-β1 modulates the chemokine receptor repertoire of human resting NK cells. J Immunol (2013) 190:5321-8. doi:10.4049/jimmunol.1202693
184. Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A (2003) 100:4120-5. doi:10.1073/pnas.0730640100
185. Lee J-C, Lee K-M, Kim D-W, Heo DS. Elevated TGF-h1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol (2004) 2004(172):7335-40. doi:10.4049/jimmunol.172.12.7335
186. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol (1986) 136:3916-20
187. Bellone G, Aste-Amezaga M, Trinchieri G, Rodeck U. Regulation of NK cell functions byTGF-h1. J Immunol (1995) 155:1066-73
188. Park YP, Choi SC, Kiesler P, Gil-Krzewska A, Borrego F, Weck J, et al. Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1. Blood (2011) 118:3019-27. doi:10.1182/blood-2011-04-346825
189. Song H, Hur DY, Kim KE, Park H, Kim T, Kim CW, et al. IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway. Cell Immunol (2006) 242:39-45. doi:10.1016/j.cellimm.2006.09.002
190. Geissmann F, Revy P, Regnault A, Lepelletier Y, Dy M, Brousse N, et al. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol (1999) 162:4567-75
191. Chen L, Qiu M, He W, Huang A, Liu J. Functional study of immature dendritic cells co-transfected with IL-10 and TGF-beta 1 genes in vitro. Mol Biol Rep (2012) 39:6633-9. doi:10.1007/s11033-012-1468-4
192. Sui Q, Zhang J, Sun X, Zhang C, Han Q, Tian Z. NK cells are the crucial antitumor mediators when STAT3-mediated immunosuppression is blocked in hepatocellular carcinoma. J Immunol (2014) 193:2016-23. doi:10.4049/jimmunol.1302389
193. Sun X, Sui Q, Zhang C, Tian Z, Zhang J. Targeting blockage of STAT3 in hepatocellular carcinoma cells augments NK cell functions via reverse hepatocellular carcinoma-induced immune suppression. Mol Cancer Ther (2013) 12:2885-96. doi:10.1158/1535-7163.MCT-12-1087
194. Alvarez M, Bouchlaka MN, Sckisel GD, Sungur CM, Chen M, Murphy WJ. Anti-TGF-β reveals competition between increased antitumor effects using IL-2 with mouse NK and CD8 T cells. J Immunol (2014) 193:1709-16. doi:10.4049/jimmunol.1400034
195. Linossi EM, Babon JJ, Hilton DJ, Nicholson SE. Suppression of cytokine signaling: the SOCS perspective. Cytokine Growth Factor Rev (2013) 24:241-8. doi:10.1016/j.cytogfr.2013.03.005
196. Inagaki-Ohara K, Kondo T, Ito M, Yoshimura A. SOCS, inflammation, and cancer. JAKSTAT (2013) 2:e24053. doi:10.4161/jkst.24053
197. Yoshimura A, Suzuki M, Sakaguchi R, Hanada T, Yasukawa H. SOCS, inflammation, and autoimmunity. Front Immunol (2012) 3:20. doi:10.3389/fimmu.2012.00020
198. Johnston JA. Are SOCS suppressors, regulators, and degraders? J Leukoc Biol (2004) 75:743-8. doi:10.1189/jlb.1003507
199. Wu WY, Kim H, Zhang CL, Meng XL, Wu ZS. Loss of suppressors of cytokine signaling 3 promotes aggressiveness in hepatocellular carcinoma. J Invest Surg (2014) 27:197-204. doi:10.3109/08941939.2013.873098
200. Isomoto H. Epigenetic alterations in cholangiocarcinoma-sustained IL-6/STAT3 signaling in cholangiocarcinoma due to SOCS3 epigenetic silencing. Digestion (2009) 79(Suppl 1):2-8. doi:10.1159/000167859
201. Kim MH, Kim MS, Kim W, Kang MA, Cacalano NA, Kang SB, et al. Suppressor of cytokine signaling (SOCS) genes are silenced by DNA hypermethylation and histone deacetylation and regulate response to radiotherapy in cervical cancer cells. PLoS One (2015) 10:e0123133. doi:10.1371/journal.pone.0123133
202. Boosani CS, Agrawal DK. Methylation and microRNA-mediated epigenetic regulation of SOCS3. Mol Biol Rep (2015) 42:853-72. doi:10.1007/s11033-015-3860-3
203. Lindemann C, Hackmann O, Delic S, Schmidt N, Reifenberger G, Riemenschneider MJ. SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation. Acta Neuropathol (2011) 122:241-51. doi:10.1007/s00401-011-0832-0
204. Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F, Markwarth A, et al. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene (2005) 24:6699-708. doi:10.1038/sj.onc.1208818
205. He B, You L, Xu Z, Mazieres J, Lee AY, Jablons DM. Activity of the suppressor of cytokine signaling-3 promoter in human non-small-cell lung cancer. Clin Lung Cancer (2004) 5:366-70. doi:10.3816/CLC.2004.n.015
206. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A (2003) 100:14133-8. doi:10.1073/pnas.2232790100
207. Yu H, Liu Y, McFarland BC, Deshane JS, Hurst DR, Ponnazhagan S, et al. SOCS3 deficiency in myeloid cells promotes tumor development: involvement of STAT3 activation and myeloid-derived suppressor cells. Cancer Immunol Res (2015) 3:727-40. doi:10.1158/2326-6066.CIR-15-0004
208. Liu X, Qu X, Chen Y, Liao L, Cheng K, Shao C, et al. Mesenchymal stem/stromal cells induce the generation of novel IL-10-dependent regulatory dendritic cells by SOCS3 activation. J Immunol (2012) 189:1182-92. doi:10.4049/jimmunol.1102996
209. Braunschweig A, Poehlmann TG, Busch S, Schleussner E, Markert UR. Signal transducer and activator of transcription 3 (STAT3) and suppressor of cytokine signaling (SOCS3) balance controls cytotoxicity and IL-10 expression in decidual-like natural killer cell line NK-92. Am J Reprod Immunol (2011) 66:329-35. doi:10.1111/j.1600-0897.2011.00989.x
210. Xu X, Wang Q, Deng B, Wang H, Dong Z, Qu X, et al. Monocyte chemoattractant protein-1 secreted by decidual stromal cells inhibits NK cells cytotoxicity by up-regulating expression of SOCS3. PLoS One (2012) 7:e41869. doi:10.1371/journal.pone.0041869
211. Shuai K, Liu B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol (2005) 5:593-605. doi:10.1038/nri1667
212. Levy C, Lee YN, Nechushtan H, Schueler-Furman O, Sonnenblick A, Hacohen S, et al. Identifying a common molecular mechanism for inhibition of MITF and STAT3 by PIAS3. Blood (2006) 107:2839-45. doi:10.1182/blood-2005-08-3325
213. Wang L, Banerjee S. Differential PIAS3 expression in human malignancy. Oncol Rep (2004) 11:1319-24
214. Brantley EC, Nabors LB, Gillespie GY, Choi YH, Palmer CA, Harrison K, et al. Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin Cancer Res (2008) 14:4694-704. doi:10.1158/1078-0432.CCR-08-0618
215. Kluge A, Dabir S, Vlassenbroeck I, Eisenberg R, Dowlati A. Protein inhibitor of activated STAT3 expression in lung cancer. Mol Oncol (2011) 5:256-64. doi:10.1016/j.molonc.2011.03.004
216. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol (2002) 168:466-74. doi:10.4049/jimmunol.168.1.466
217. Dabir S, Kluge A, Kresak A, Yang M, Fu P, Groner B, et al. Low PIAS3 expression in malignant mesothelioma is associated with increased STAT3 activation and poor patient survival. Clin Cancer Res (2014) 20:5124-32. doi:10.1158/1078-0432.CCR-14-1233